Table 5.
Patient characteristics for vaccinated samples
| BMI < 25 kg m−2 (n = 26) | BMI ≥ 25 kg m−2 (n = 21) | ||||
|---|---|---|---|---|---|
| Mean (IQR) | % | Mean (IQR) | % | P‐value | |
| Age | 46.46 (27.25–63.75) | – | 43.81 (29.00–60.00) | – | 0.9282 |
| Sex (male/female) | 6/20 | 23.07 | 11/10 | 52.38 | 0.03765 |
| Time post vaccination a (months) | 4.55 (3.68–5.35) | – | 5.14 (3.27–5.47) | – | 0.5560 |
| N Ab detected (Y/N) | 7/19 | 26.9 | 8/13 | 38.09 | 0.4140 |
| Vaccination type b (P/AZ) | 15/11 | 57.69 | 14/7 | 66.67 | 0.5292 |
| BMI | 22.22 (21.00–23.95) | – | 32.04 (26.8–36.7) | – | < 0.0001 |
a
Time post vaccination calculated from the second vaccination dose.
b
P, Pfizer‐BioNTech; AZ, Oxford/AstraZeneca (ChAdOx1‐S Recombinant vaccine).